Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the DEA quota changes or opioid litigation disclosures hidden inside Collegium Pharmaceutical’s 300-page 10-K can drain hours. Clinical trial updates, royalty obligations for Xtampza ER, and milestone payments tied to Jornay PM all sit deep in footnotes—exactly where critical risk factors often lurk.
Stock Titan decodes those complexities instantly. Our AI reads every Collegium Pharmaceutical quarterly earnings report 10-Q filing, pulls out segment revenue for the Nucynta franchise, and highlights changes in Schedule II inventory accounting. Wondering about Collegium Pharmaceutical insider trading Form 4 transactions? Get real-time alerts the moment executives buy or sell, plus plain-English explanations of what each trade might signal. We cover the full spectrum—10-K annual report, 8-K material events, S-8 equity plans, and the proxy statement executive compensation that explains how opioid-risk metrics influence bonuses—all updated the second EDGAR posts.
Use our platform to:
- Track Collegium Pharmaceutical Form 4 insider transactions in real time
- Compare DETERx® royalty expense trends quarter over quarter
- Read AI-powered summaries that make the Collegium Pharmaceutical annual report 10-K simplified
- See every 8-K material events explained—from FDA label expansions to legal settlements
The Schedule 13G/A filed for Collegium Pharmaceutical shows Principal Global Investors beneficially owns 1,466,506 shares of Collegium common stock, representing 4.6% of the class. The filing reports shared voting power and shared dispositive power for all 1,466,506 shares and no sole voting or dispositive power. The issuer is identified as Collegium Pharmaceutical (common stock, $0.001 par). The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) disclosed in an 8-K filed on July 1, 2025 that its Board authorized a new share repurchase program of up to $150 million of common stock, effective immediately and running through December 31, 2026.
The company intends to execute buybacks on the open market at management’s discretion, considering prevailing market conditions and share price. Funding will come exclusively from existing cash on hand; no additional debt or equity issuance is mentioned. The filing contains no earnings figures, operational updates, or changes to prior guidance.
While the authorization does not obligate the company to repurchase the full amount, the program could reduce the share count, provide support for the stock price, and signal management’s confidence in long-term prospects. Investors should note that the timing, pace, and ultimate utilization of the $150 million limit remain subject to market dynamics and internal capital allocation priorities.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
